Gilman’s Next CEO Trick: Taming CAR-T Cells With Obsidian – Xconomy
|
Gilman’s Next CEO Trick: Taming CAR–T Cells With Obsidian
Xconomy Genetically modified medicine is here. Two CAR-T therapies, made from a patient’s living T cells, are on the market in the U.S., and many more are in various stages of clinical testing. As remarkable as they might seem, however, these medicines are … |
pharmaphorum |
ASH 2017: CAR–T therapy and beyond
pharmaphorum As the American Society of Hematology’s 2017 congress approaches, there’s plenty to be excited about – not just in blood cancer, but in previously overlooked diseases such as sickle cell anaemia and haemophilia. Richard Staines finds out more from … |
Proactive Investors UK |
GSK’s latest phase III shingles trial offers hope to stem cell transplant patients
Proactive Investors UK The ZOE-HSCT phase III study tested the vaccine on adults over the age of 18 who had just undergone autologous haematopoietic stem cell transplant (auHSCT). It succeeded in its primary objective, demonstrating that Shingrix reduced the chances of … GSK: Phase III Data Supports Efficacy Of Shingrix In Preventing ShinglesNasdaq |
Triangle Business Journal |
Big apple-based biotech’s new gene therapy subsidiary inks UNC licensing deals
Triangle Business Journal Fortress’ new subsidiary – New York-based Tamid Bio – will focus on the development of adeno-associated virus (AAV) gene therapies for the treatment of rare orphan diseases, according to the company. AAV’s use in gene therapy is particularly popular … |